International Health Sciences Review · Jul 17, 2026
Comparative incidence of sarcopenia across distinct GLP-1 receptor agonists in non-diabetic populations
By Borges VCM, Araújo GFM, Duarte PGDPL et al.
Incretin-based therapies, including GLP-1 receptor agonists and dual GIP/GLP-1 co-agonists, have revolutionized weight management. Despite significant efficacy, rapid weight loss raises concerns regarding lean body mass (LBM) depletion and sarcopenic risk. This review synthesizes clinical evidence comparing the musculoskeletal outcomes of semaglutide, liraglutide, and tirzepatide in non-diabetic populations. Clinical trials and real-world EHR phenotyping confirm that these therapies induce weight loss characterized by a consistent partitioning ratio—approximately 75% fat and 25% lean mass loss. However, tirzepatide exhibits greater absolute LBM reduction than semaglutide in routine care, a phenomenon potentially linked to broader GIPR cellular distribution in human musculature. Digital phenotyping reveals distinct metabolic trajectories; while many patients achieve a "Prime GLP-1 metabotype" (high TBW loss with low LBM loss), a "Depletive GLP-1 metabotype" (>20% TBW loss with >5% LBM loss) occurs more frequently with tirzepatide. Baseline musculoskeletal pain acts as a significant predictor of accelerated LBM decline, which correlates with reduced real-world exercise tolerance and increased clinical fatigue. Conversely, incretin therapy can reduce the prevalence of sarcopenic obesity and mitigate myosteatosis, with preclinical models confirming preserved mitochondrial health. We advocate for shifting to an integrated "quality of weight loss" framework. Future care must prioritize musculoskeletal preservation through resistance training and nutritional optimization, interpreting LBM changes alongside functional markers to ensure the long-term durability of obesity pharmacotherapy.